IPH4102 for Cutaneous T-Cell Lymphoma
(TELLOMAK Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This is an open label, multi-cohort, and multi-center phase II study, which evaluates the clinical activity and safety of IPH4102 in Sezary Syndrome and Mycosis fungoides as single agent.
Will I have to stop taking my current medications?
The trial requires a minimum washout period (time without taking certain medications) of 3 weeks between the last dose of your previous systemic therapy and the first dose of IPH4102. This means you will need to stop taking your current systemic medications for at least 3 weeks before starting the trial treatment.
Is IPH4102 safe for humans?
What data supports the effectiveness of the drug IPH4102 for treating cutaneous T-cell lymphoma?
The research highlights the need for new treatments for cutaneous T-cell lymphoma (CTCL) due to the high relapse rates and lack of curative therapies. Recent advances in understanding the disease's biology have led to the development of new systemic drugs and treatment strategies, suggesting that innovative approaches like IPH4102 could potentially be effective.678910
Are You a Good Fit for This Trial?
This trial is for adults with advanced T Cell Lymphoma, specifically Sezary Syndrome and Mycosis fungoides, who have tried at least two other treatments. They must be in good enough health to undergo a biopsy, not have had certain recent treatments or vaccines, no major surgery within the last month, and no active severe infections or other cancers in the past five years.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
IPH4102 is administered every week for 5 weeks, then every 2 weeks for 10 administrations, and then every 4 weeks until disease progression or unacceptable toxicity
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- IPH4102
Find a Clinic Near You
Who Is Running the Clinical Trial?
Innate Pharma
Lead Sponsor